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clopidogrel response and post-stent complications among Egyptian patients scheduled for PCI. In
addition, to assess post-clopidogrel platelet reactivity (PPR) as a predictor of post-stent complica-
tions.
Subjects and methods: This study included 45 patients scheduled for elective PCI at Ain Shams
University Hospital. All the studied patients were subjected to detection of CYP3A5 A6986G poly-
morphism and assessment of clopidogrel response using adenosine diphosphate (ADP)-induced
platelet aggregation.
Results: Wild, heterozygous and homozygous genotypes were detected in 2.2%, 31.1% and 66.7%
of the patients, respectively. A trend for lower PPR in expressor genotype group was found
(p= 0.08). No inﬂuence of the CYP3A5 genotypes on post-stent complications was found
(p= 1.0). Clinical presentation, smoking, previous acute coronary syndrome (p< 0.05) were the
main inﬂuencing factors of the PPR. Logistic regression analysis demonstrated that the stent lengthl.com (A.M. Abd Elsalam).
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24 A.A. Saad et al.and PPR are the main predictors for post-stent complications (95% CI = 1.014–1.950 and 0.999–
1.181; p= 0.04 and 0.05, respectively).
Conclusion: CYP3A5 genetic polymorphism does not contribute to the observed variability in the
inhibitory effect of clopidogrel. Low response to clopidogrel is a novel risk factor for ischemic
events after PCI. The evaluation of low response to clopidogrel may help to identify patients at
increased risk that may beneﬁt from intensiﬁed antiplatelet strategy.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Platelets play a pivotal role in the pathogenesis of athero-
thrombotic events. Patients undergoing PCI with stent implan-
tation are at an increased risk of thrombosis sometimes
complicated by acute myocardial infarction or death. It is esti-
mated that more than 1 million percutaneous coronary inter-
vention (PCI) procedures are performed annually worldwide
and that most (70%) involve stent implantation.1 Inhibition
of platelet aggregation is therefore a primary therapeutic goal.2
Clopidogrel therapy has proven cardiovascular beneﬁt in
an increasing number of clinical scenarios. Clopidogrel reduces
cardiovascular events in patients with stable atherosclerotic
disease, patients with acute coronary syndromes (ACS)
whether ST-elevation myocardial infarction (STEMI) or non-
STEMI, and in patients undergoing PCI.3
In order to acquire its antiplatelet effect, clopidogrel requires
oxidation by the hepatic cytochrome P450 3A (CYP3A) to gen-
erate an active metabolite. Clopidogrel inhibits platelet activa-
tion through irreversible binding to theplatelet P2Y12 receptor.4
However, many observations have also shown marked
interindividual variability in clopidogrel inhibition of ADP-in-
duced platelet aggregation, and it has been estimated that up
to 30% of patients do not achieve an adequate antiplatelet ef-
fect from the initial clopidogrel load. The cause of individual
heterogeneity to clopidogrel is unknown, although clopidogrel
resistance has recently been suggested as a possible cause.5
Putative explanations of clopidogrel resistance include
drug–drug interaction or genetic polymorphisms of the drug-
metabolizing enzyme involved in the metabolism of clopido-
grel. Because clopidogrel must be metabolized by CYP3A to
acquire its responsiveness, defective CYP3A enzymes have
the potential to impair the effect of clopidogrel.6
The CYP3A subfamily (P450 3A) consists of the 3A5
enzyme and three other isoforms, namely CYP3A4, CYP3A7
and CYP3A43, as well as two pseudogenes, CYP3AP1 and
CYP3AP2.7 Functional activity of CYP3A4 and 3A5 varies
considerably in various populations, with negligible contribu-
tions from CYP3A43 and CYP3A7 isoforms.
The gene encoding for CYP3A5 is located on the 7q22.1
chromosome.8 Gene variants of CYP3A5 are responsible for
major individual differences in CYP3A enzymatic activity,
strongly inﬂuencing pharmacokinetics and bioavailability of
an array of drugs.9 The most frequent single nucleotide poly-
morphism (SNP) of functional importance in the CYP3A5
gene is the A to G transition in intron 3 at position 6986
(CYP3A5*3).10 This variant leads to alternative splicing site
with impaired protein synthesis, resulting in a decrease in met-
abolic activity. Conversely, the presence of the wild-typeA6986 allele (CYP3A5*1) leads to the phenotype of high
CYP3A5 catalytic activity. The frequency of the CYP3A5*3
variant differs among populations and races.11
The aims of the present work were to study the effect of
CYP3A5 polymorphism on clopidogrel response and post-
stent complications among Egyptian patients scheduled for
PCI and to assess post-clopidogrel platelet reactivity (PPR)
as a predictor of post-stent complications.
2. Subjects and methods
This study was conducted on 45 cardiac patients in the period
from September 2008 to June 2009 at Ain Shams University
Hospital. The study protocol was approved by Ain Shams
Medical Research Ethical Committee.
Patients enrolled in this study were scheduled for elective
PCI. A loading dose of 300 mg clopidogrel was given to all
patients prior to PCI followed by a daily dose of 75 mg for at
least 3 months. All patients had undergone successful coronary
angioplasty with implantation of bare-metal stents (stainless-
steel or cobalt–chromium alloy) according to current standard
guidelines. Patients who had complications during the proce-
dure that may induce a bias in the trial were excluded. Patients
were on routine medical treatment which includes nitrates, beta
blockers, aspirin 162 mg/day, lipid lowering drugs, and various
types of antihypertensives mainly ACEIs for hypertensive pa-
tients as well as hypoglycemic agents for diabetic cases. Clinical
follow-up information, including clopidogrel status, was
obtained by contacting all patients at 30 days and 6 months
postprocedure for detection of any stent complications.
All the study participants were subjected to full detailed his-
tory and careful clinical examination, complete blood count
(Coulter LH 750 analyzer, Beckman Coulter, CA, USA), liver
function (serum alanine transferase) and kidney function test
(serum creatinine) using Synchron CX-7 (Beckman, Switzer-
land), assessment of risk factors: serum glucose level and
serum cholesterol level using Synchron CX-7 (Beckman, Swit-
zerland), determination of cytochrome P450 3A5 genotype by
high resolution LightCycler 480 as well as assessment of PPR
by ADP-induced platelet aggregation using light transmittance
aggregometry.
Patients were excluded if they had suffered a clinically
signiﬁcant illness within 4 weeks prior to enrolment, taken
any antiplatelet treatment (excluding aspirin) within 10 days
prior to PCI, a known allergy or intolerance to clopidogrel,
a platelet count <100 · 109/l, abnormal kidney or liver func-
tion test, a history of major surgery or trauma within the
preceding 3 months. Other exclusion criteria was left ventricu-
lar ejection fraction <40%.
Effect of cytochrome P450 3A5 polymorphism 252.1. Deﬁnition of endpoints
The clinical endpoint included all the following CV events: the
occurrence of death from any cause, ACS, acute and subacute
stent thrombosis. ACS was deﬁned by the presence of symp-
toms compatible with recurrent ischemia requiring re-hospital-
ization and coronary angiography. Subacute stent thrombosis
was deﬁned as stent thrombosis occurring after discharge to
30 day follow-up, and late-stent thrombosis was deﬁned as
stent thrombosis occurring between 30 day and 6-month
follow-up. Follow-up information was collected through con-
tacts with the patients by the phone.
2.2. Sampling
Peripheral venous blood samples (4 ml) were collected from
patients at the time of catheterization using two vacutainer
tubes, one containing anticoagulant potassium ethylene
diamine tetra-acetate (EDTA) in a ﬁnal concentration of
1.5 mg/ml for PCR and the other containing 0.2 ml of sodium
citrate 3.8% (9 volumes of blood to 1 volume of citrate).
2.3. Methods
2.3.1. Cytochrome P450 3A5 genotype detection by high
resolution LightCycler 480
RNA was extracted immediately according to manufacture’s
instructions using MagNA pure compact nucleic acid isolation
kit (Roche Diagnostics, Germany, Cat. No. 03730964001) and
MagNA pure compact instrument. The yield of RNA obtained
was determined spectrophotometrically.
The primers used were: forward: 50-CTT TAAAGA GCT
CTT TTG TCT CTC A-30; reverse: 50-CCA GGA AGC CAG
ACTTTGAT-30. A ﬁnal reaction volume of 20 ll was prepared
using LightCycler-DNA Master SYBR Green I kit (Roche
Diagnostics, Germany, Cat. No. 2015099). It is a ready-to-use
reaction mix for PCR. Ampliﬁcation was done in LightCycler
480 Gene Scanning Software based on melting curve analysis
at high resolution (Roche Diagnostics, Germany).
2.3.2. Determination of clopidogrel response using adenosine
diphosphate (ADP)-induced platelet aggregation
Platelet-rich plasma was obtained by centrifugation of the
whole blood for 10 min at 1000 rpm. The remaining blood
was re-centrifuged at 3000 rpm for 10 min to obtain platelet-
poor plasma (PPP).
Platelet aggregation was assayed using turbidimetric aggre-
gometer (Chorono-Log 450, Coulter, USA). Aggregation is in-
duced by addition of 50 ll of 5 lmol/l ADP (Helena
BioScience, UK) to 450 ll of PRP of each sample. Aggregation
was expressed as the maximal percentage change in light trans-
mittance from baseline with PPP as reference (100% aggrega-
tion). Platelet aggregation was evaluated considering the
maximal percentage of platelet aggregation in response to
stimulus. Results were expressed as percentage of maximal
light transmission using platelet-poor plasma from the same
patient as reference (100% aggregation).
Samples from 45 healthy volunteers of matched age and
gender who had not taken medications or antiplatelet drugs
for the preceding 2 weeks were run to determine the median
normal reference laboratory aggregation value that was 61%.2.4. Statistical analysis
Analysis of data was done by IBM computer using Statisti-
cal Program for Social Science version 15 (SPSS Inc., Chi-
cago, IL, USA) as follows: Description of quantitative
variables as mean, SD, median and range and description
of qualitative variables as number and percent. Chi-square
test and Fisher’s exact test (when any expected cell count
was less than 5) were used to compare between groups
regarding CYP3A5 genotype. Student’s t-test was used to as-
sess the statistical signiﬁcance of the difference between
groups as regards the mean value of age. Comparisons of
the effect of PPR was analyzed using non-parametric tests
(Mann–Whitney and Kruskal–Wallis). Pearson’s correlation
coefﬁcients were calculated to study the correlation between
PPR and age, the stent length and diameter. The predictive
capability of the index was assessed using the receiver oper-
ating characteristic curve (ROC curve); it is a plot of sensi-
tivity against 1 – speciﬁcity and the area under the curve is
measured. The area under the curve is a measure of the
overall discriminatory power of the platelets. Logistic regres-
sion analysis was used to predict the clinical endpoint.
Probability or p value of <0.05 was considered statistically
signiﬁcant, while p value <0.001 was considered statistically
highly signiﬁcant.
3. Result
The results of the present study are shown in Tables 1–4 and
Figs. 1 and 2. This study was conducted on 45 CHD patients
their age ranged from 38 to 67 years with a mean of
52 ± 7.9 years. They were 33 males and 12 females with male
to female ratio 2.75:1.
3.1. Distribution of CYP3A5 genotypes and their statistical
association with patients’ characteristics (Table 1)
Considering the CYP3A5 allele expression distribution among
the studied patients, wild allels (AA) was detected in 1 (2.2%)
patient, heterozygous mutation (AG) was detected in 14
(31.1%) patients and homozygous mutation (GG) was de-
tected in 30 (66.7%) patients. Accordingly, patients were clas-
siﬁed into two groups; patients expressing A allele (AA and
AG) as one group and non-expressors (GG) as the other
group.
There were statistically insigniﬁcant differences in demo-
graphics or clinical attributes when subjects were grouped
according to CYP3A5 genotype (p> 0.05).
A trend for lower PPR (better response to clopidogrel) in
expressor genotype group (AA/AG) was found but with bor-
derline p value (p= 0.08).
3.2. Association between PPR and patients’ characteristics
(Table 2)
PPR was deﬁned as the percent aggregation on clopidogrel (at
the time of catheterization prior to PCI in patients already on
clopidogrel 24 h before the procedure). Statistically signiﬁ-
cantly higher PPR were found in patients presented with
STEMI, current smokers and patients with history of previous
ACS (p= 0.003, 0.04 and 0.05, respectively).
Table 1 Relation between CYP3A5 genotype and patients characteristics.
Parameter – n (%) AG/AA (n= 15) GG (n= 30) p
Gender 0.1
Male 9(27.3) 24(72.7) v2 = 2.045
Female 6(50.0) 6(50.0)
Age – mean ± SD (years) 54.0 ± 9.1 51.0 ± 7.1 t= 1.205 0.2
Premature onset CHD 0.1
Yes 10(27.8) 26(77.2) Fisher’s test
No 5(55.6) 4(44.4)
Clinical presentation 1
UA/NSTEMI 13(34.2) 25(65.8) Fisher’s test
STEMI 2(28.6) 5(72.4)
No. of vessels aﬀecteda 0.2
One 7(26.9) 19(73.1) v2 = 2.631
Two 7(50.0) 7(50.0)
Multivessel 1(20.0) 4(80.0)
No. of lesions/patienta 0.9
One 7(35.0) 13(65.0) v2 = 0.096
Two 6(33.3) 12(66.7)
Three 2(28.6) 5(71.4)
PPR – median (%) 13 22 Z= 1.748 0.08
n: number; CHD: coronary heart disease.
a Linear by linear association.
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sion, diabetes mellitus (DM) and hypercholesterolemia but p
values did not reach statistically signiﬁcant level (p= 0.7,
0.08, 0.2, respectively).
Correlation study revealed statistically insigniﬁcant relation
between PPR and age, stent length and diameter (p= 0.7, 0.7
and 0.5).
Statistically insigniﬁcant association between PPR and pre-
mature onset CHD, the number of affected vessels and the
number of lesions per patient were found (p> 0.05).
3.3. Estimation of the PPR best cut-off point for deducing the
clinical end point (Table 3, Fig. 1)
ROC curve analysis demonstrated that PPR was able to distin-
guish between patients with and without post-stent complica-
tions (area under the curve 0.832, 95% conﬁdence interval
0.715–0.948). PPR equals 18.5% was identiﬁed as the optimal
cut-off value to predict post-discharge 6-month post-stent
complications, providing a sensitivity of 100% and a speciﬁcity
of 63%. All complicated cases were above this value
(p< 0.001). This cut-off point was lower than the median
value of PPR (20%) which when applied for stratiﬁcation of
the patients, two complicated cases were found to be below
it providing 87% sensitivity and 69% speciﬁcity (p= 0.007).
On the other hand, stratiﬁcation of the patients according to
the 75th percentile revealed insigniﬁcant relation to post-stent
complications (p= 0.2). In addition, ADP-induced platelet
aggregation for 45 healthy subjects were used to achieve the
best deﬁnition of clopidogrel response; none of the studied
patients were above the 75th (70%) percentile of the control
group and only two patients were above the 50th (61%)
percentile or the median value. Furthermore, categorization
of the patients according to the 25th percentile value of the
control (56%) showed statistically insigniﬁcant association
with the post-stent complications (p= 0.1).3.4. Predictors of post-stent complications (Tables 3 and 4)
The incidence of 6-month post-stent complications was 28.9%.
Patients who developed post-stent complications had statisti-
cally signiﬁcantly higher PPR (32% versus 16.5% for non-
complicated cases (p= 0.001).
Patients complicated with post-stent complications had
statistically signiﬁcant greater incidence of STEMI, multivessel
disease, multiple lesions per patient, DM and history of previ-
ous ACS (0.01, 0.001, 0.002, 0.007 and 0.004, respectively).
Moreover, the median stent length per patient of the compli-
cated group was superior to the one of the non-complicated
group (p= 0.01).
In this study, neither the age nor premature onset CHD
showed statistically signiﬁcant association with post-stent
complications. Furthermore, there were no statistically signif-
icant differences in the post-stent complications rate among
smokers, hypertensive, hypercholesterolemic and overweight
patients. We also found no inﬂuence of the CYP3A5 genotypes
or stent diameter on post-stent complications (p= 0.4 and
1.0).
Logistic regression was done (using clinical presentation,
number of lesions, DM, PPR and stent length) demonstrated
that the stent length and PPR are the main predictors for
post-stent complications (95% CI = 1.014–1.950 and 0.999–
1.181; p= 0.04 and 0.05, respectively).
4. Discussion
The aim of the present work is to study the effect of CYP3A5
polymorphism on clopidogrel response and post-stent compli-
cations among Egyptian patients scheduled for PCI. In addi-
tion, to assess PPR as a predictor of post-stent complications.
The frequency of the CYP3A5 (GG) variant differs among
populations and races, ranging from 27–50% in the Afro-
American population, 60–70% among Asians, and up to
Table 2 Association between PPR and patients characteristics.
Parameter ADP-aggregation median (%) Test of signiﬁcance p
Gender 0.1
Male: n= 33 22 Z= 1.336
Female: n= 12 16.5
Age (years) r= 0.049 0.7
Premature onset CHD 0.7
Yes: n= 36 20 Z= 0.384
No: n= 9 19.5
Clinical presentation 0.003
UA/NSTEMI: n= 38 18 Z= 2.979
STEMI: n= 7 32
No. of vessels aﬀected 0.2
One: n= 26 20 v2 = 3.134
Two: n= 14 18
Multivessel: n= 5 51
No. of lesions/patient 0.3
One: n= 20 16.5 v2 = 2.357
Two: n= 18 25
Three: n= 7 19
Current smoking 0.04
Yes: n= 25 26 Z= 2.058
No: n= 20 18.5
Hypertension 0.7
Yes: n= 30 25 Z= 0.313
No: n= 15 18
DM 0.08
Yes: n= 23 25 Z= 1.705
No: n= 22 18
Hypercholesterolemia 0.2
Yes: n= 23 25 Z= 1.205
No: n= 22 18
Overweight 0.4
Yes: n= 12 21.5 Z= 0.771
No: n= 33 20
Previous ACS 0.05
Yes: n= 8 35 Z= 1.902
No: n= 27 20
Stent length (mm) r= 0.045 0.7
Stent diameter (mm) r= 0.093 0.5
Post-stent complication 0.001
Yes: n= 13 32 Z= 3.460
No: n= 32 16.5
n: number; CHD: coronary heart disease; UA: unstable angina; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-
segment elevation myocardial infarction; DM: diabetes mellitus; ACS: acute coronary syndrome.
Effect of cytochrome P450 3A5 polymorphism 2785–95% in individuals of Caucasian ancestry, in which the
expressor variant is uncommon.12 In the present work,
CYP3A5 allele expressors group represent 33.3% of the stud-
ied patients. This frequency is slightly higher than Smith
et al.11 who studied 109 UK patients and Frere et al.13 who
studied 603 French patients but lower than Suh et al.14 who
studied 348 Korean patients. This conﬁrms the trend described
of the notably increasing gradient of CYP3A5*1 allele
frequency from north to south of the globe.10
We investigated whether common sequence variations in
the CYP3A5 had inﬂuence in demographics or clinical attri-
butes of the studied patients and we found insigniﬁcant differ-
ence between expressors and non-expressors group. This is in
accordance with Suh et al.14
In our work a trend for lower PPR in expressor genotype
group (AA/AG) was found but with borderline p value. Smith
et al.11 found that CYP3A5 genotype signiﬁcantly inﬂuenceclopidogrel efﬁcacy. However, Angiolillo et al.15 found that
gene sequence variations of the CYP3A5 enzyme in patients
with coronary artery disease have not been associated with
variability in clopidogrel responsiveness. This observation
may be explained by the fact that CYP3A4 is the dominant
CYP3A enzyme in whites and therefore may be more impor-
tant in clopidogrel metabolism.
We were the ﬁrst to disclose that these polymorphisms do
not contribute to the occurrence of post-stent complications.
In study by Suh et al.,14 atherothrombotic events occurred
more frequently among patients with the CYP3A5 non-expres-
sor genotype. A large clinical study would be necessary to
investigate the potential inﬂuence of cytochrome polymor-
phisms on clinical events.
We deﬁned PPR as the percent of 5 lmol/l ADP-induced
platelet aggregation at the time of catheterization prior to
PCI in patients already on clopidogrel at least 24 h before
Table 3 Predictors of post-stent complications.
Parameter – n (%) Uncomplicated (n= 32) Complicated (n= 13) Test of signiﬁcance p
Gender 0.7
Male 24(72.7) 9(27.3) Fisher’s test
Female 8(66.7) 4(33.3)
Age – mean ± SD (years) 50.8 ± 6.4 54.7 ± 10.5 t= 1.518 0.1
Premature onset CHD 1
Yes 25(69.4) 11(30.6) Fisher’s test
No 7(77.8) 2(22.2)
Clinical presentation 0.01
UA/NSTEMI 30(78.9) 8(21.1) Fisher’s test
STEMI 2(28.6) 5(71.4)
No. of vessels aﬀecteda 0.001
One 22(84.6) 4(15.4) v2 = 11.212
Two 10(71.4) 4(28.6)
Multivessel 0 5(100)
No. of lesions/patienta 0.002
One 18(90) 2(10) v2 = 9.345
Two 12(66.7) 6(33.3)
Three 2(28.6) 5(71.4)
Current smoking 0.1
Yes 20(80) 5(20) v2 = 2.163
No 12(60) 8(40)
Hypertension 0.4
Yes 20(66.7) 10(33.3) Fisher’s test
No 12(80) 3(20)
DM 0.007
Yes 12(52.2) 11(47.8) Fisher’s test
No 20(90.9) 2(9.1)
Hypercholesterolemia 0.1
Yes 14(60.9) 9(39.1) Fisher’s test
No 18(81.8) 4(18.2)
Overweight 0.4
Yes 10(83.3) 2(16.7) Fisher’s test
No 22(66.7) 11(33.3)
Previous ACS 0.004
Yes 2(25) 6(75) Fisher’s test
No 30(81.1) 7(18.9)
CYP3A5 1
AG/AA 11(73.3) 4(26.7) Fisher’s test
GG 21(70) 9(30)
Stent length – median (mm) 17.5 27 Z= 2.388 0.01
Stent diameter – median (mm) 3.1 3 Z= 0.789 0.4
PPR upper quartile 0.1
Responders (<33%) 26(76.5) 8(23.5) v2 = 1.945
Non-responders (P33%) 6(54.5) 5(45.5)
PPR middle quartile (median) 0.007
Responders (<20%) 20(90.9) 2(9.1) Fisher’s test
Non-responders (P20%) 12(52.2) 11(47.8)
PPR according to the ROC curve <0.001
Responders (<18.5%) 20(100) 0 Fisher’s test
Non-responders (P18.5%) 12(48) 13(52)
PPR lower quartile of the control 0.1
Responders (<56%): n= 40 30(75) 10(25) Fisher’s test
Non-responders (P56%): n= 5 2(40) 3(60)
n: number; CHD: coronary heart disease; UA: unstable angina; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-
segment elevation myocardial infarction; DM: diabetes mellitus; ACS: acute coronary syndrome. PPR: post-clopidogrel platelet reactivity.
a Linear by linear association.
28 A.A. Saad et al.the procedure. Response to clopidogrel deﬁnition is not
consensual and can be based on the change in ADP-induced
maximal intensity of platelet aggregation before and after the
initiation of clopidogrel therapy and the cut-off value to
identify low responders varied from <10% to <40%.5,16,17This evaluation method is not always suitable for daily clinical
practice. In addition, other studies have shown that pretreat-
ment platelet activity did not predict the clopidogrel respon-
siveness, these studies have also shown the correlation
between a low response to clopidogrel (difference between
Table 4 Binary logistic regression for the predictors of post-
stent complications.
Parameter OR 95% CI for OR p
Clinical presentation 0.565 0.036–8.788 0.6
DM 48.322 0.166–14083.971 0.1
PPR 1.086 0.999–1.181 0.05
Stent length 1.406 1.014–1.950 0.04
N of lesions/patient 11.614 0.644–209.348 0.09
Constant 0.000 0.02
SEM: standard error of the mean; CI: conﬁdence interval; DM:
diabetes mellitus; N: number.
Figure 1 ROC curve for estimation of the PPR best cut-off point
for deducing the clinical end point.
Figure 2 Melting curve of CYP3A5 genotypes: blue line, wild (low m
temperature) and purple line, homozygous (high melting temperature)
Effect of cytochrome P450 3A5 polymorphism 29pre- and post-treatment values) and high PPR which was
proposed as a better estimate of thrombotic risk.18,19 Therefore
we choose to identify clopidogrel effect with ADP-induced
platelet aggregation testing on one single blood sample at the
PCI-time without baseline to identify a clinically based
threshold.
In our work, ROC analysis demonstrated that PPR of 18.5
was the optimal cut-off value to predict post-discharge
6-month stent complications providing a sensitivity of 100%
and a speciﬁcity of 63%, i.e. all complicated cases were above
this value. This value is slightly higher than the cut-off ob-
tained by Hochholzer et al.20 who studied 802 patients and
showed that PPR above the median value (14%) after stimula-
tion by 5 lmol/l carried a 6.7-fold increase in major adverse
cardiac events (death, myocardial infarction, and target vessel
revascularization) at 1-month follow-up. In our study, applica-
tion of median value of PPR (20%) for stratiﬁcation of the
patients, two complicated cases were found to be below it pro-
viding 87% sensitivity and 69% speciﬁcity. Therefore, it might
be for the patients’ sake to lower the cut-off value to segregate
low responders from responders but if around half of the pa-
tients are not optimally treated and therefore might beneﬁt
from an intensiﬁed antiplatelet therapy in terms of better clin-
ical prognosis has to be critically evaluated. Besides our thresh-
old for non-responsiveness must be validated in a large
population.
However, higher residual PPR cut-off value was used by
Geisler et al.21, Cuisset et al.22 and Cuisset et al.23 (>70%).
It is important to note the most important difference between
these studies and our study is the different loading dose of clop-
idogrel; the high, 600 mg loading dose of clopidogrel may over-
come differences in drug-response observed with the 300 mg
loading dose used in our study. Moreover, most of the men-
tioned studies assessed platelet aggregation after stimulation
with 10–20 lmol/l ADP instead of 5 lmol/l used in our study.
In this work, STEMI, current smoking, previous ACS were
associated with higher PPR. Buonamici et al.24 found that
clopidogrel-nonresponsive patients were older, had a greater
incidence of DM, unstable angina, multivessel disease, lowerelting temperature); gray line, heterozygous (two peaks of melting
.
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smoking and STEMI. Larger scale clinical trials are warranted
to evaluate these prognostic measures and their implementa-
tion for therapeutic decisions. In addition, other therapeutic
approaches should be considered in these patients.
It is estimated that more than 1 million PCI procedures are
performed annually worldwide and that most involve stent
implantation Smith et al.11 In this work the incidence of
6-month bare-metal post-stent complications was 28.9%. This
is in line with Ellis et al.25 who studied 1633 patients and com-
pared the percentage of target lesion revascularization at the
7 month follow-up period in DES versus BMS and found that
in BMS group the rate was 22.8% versus 7.7% in DES. More-
over, Gurbel et al.26 found that 44/191 patients (20%) suffered
cardiovascular ischemic events within 6-month follow-up.
Higher rates were obtained by Alasfar et al.27 who studied
33 Egyptian patients who underwent PTCA and bare-metal
stenting and found that the restenosis rate was 39.7%. How-
ever lower values were obtained by Zurakowski et al.28 who
reported that restenosis at six months occurred in 10/73
(13.7%) patients and Cuisset et al.22 with 12/106 (11%) cere-
brovascular ischemic events occurred but within only 1-month
follow-up of PCI. Baseline characteristics of our studied pa-
tient may explain the relatively higher post-stent complications
rate.
In this study, patients presented with STEMI, multivessel
disease, multiple lesions, DM and history of previous ACS sig-
niﬁcantly enhances the occurrence of post-stent complications.
Moreover, the median stent length per patient of the compli-
cated group was superior to that of the non-complicated
group. Gurbel et al.5 found that the occurrence of cardiovascu-
lar ischemic event was signiﬁcantly inﬂuenced by severe LV
dysfunction, advanced age. Investigation of alternative clopi-
dogrel dosing regimens that may reduce post-stent complica-
tions in high-risk patients identiﬁed by this assay is warranted.
In keeping with Gurbel et al.,5 Gurbel et al.,26 Geisler
et al.,21 Hochholzer et al.20 who studied 96, 192, 379, 802
patients undergoing coronary stent implantation, respec-
tively, in this study, following PCI high platelet reactivity
in patients on clopidogrel is associated with post-discharge
stent complications. Besides this work logistic regression
analysis demonstrated that the stent length and PPR are
the main predictors for post-stent complications. Similarly,
Buonamici et al.24 based on multivariate analysis established
that the predictors of the stent thrombosis were non-respon-
siveness to clopidogrel, ST-segment elevation AMI, total
stent length, and LVEF. The strong predictive value of
post-stent complications provided by a single platelet aggre-
gation assessment, as revealed by our study, has important
clinical implications. Alternative revascularization strategies
or pharmacologic strategies with the aim of a more complete
P2Y12 receptor inhibition using increasing doses of clopido-
grel or other antiplatelet agents should be considered to re-
duce the risk of ischemic events.29,30
Two limitations of the present study deserve consideration:
relatively small sample size and the assessment of platelet func-
tion at a single time point prior to the intervention. Although
this time point is probably most useful in the clinical setting of
PCI, baseline measurements before loading might have pro-
vided additional information.
In conclusion CYP3A5 genetic polymorphism does not
contribute to the observed variability in the inhibitory effectof clopidogrel. Low response to clopidogrel is a novel risk fac-
tor for ischemic events after PCI. The evaluation of low
response to clopidogrel may help to identify patients at
increased risk that may beneﬁt from intensiﬁed antiplatelet
strategy. However before platelet function testing can be
widely adopted to risk stratify patients post-PCI large random-
ized clinical trials must evaluate whether the beneﬁts of an
aggressive antiplatelet therapy in non-responders outweigh
any potential risk of increased bleeding.References
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